The Patent Trial and Appeal Board (PTAB) rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews (IPRs) related to dry-eye treatment Restasis (cyclosporine ophthalmic emulsion) late last week.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
generics, Restasis, patent invalidation, Allergan, Saint Regis Mohawk Tribe, PTAB, IPR, sovereign immunity